DK0922102T3 - Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf - Google Patents
Receptor-agonister af hepatocyt-vækstfaktor og anvendelser derafInfo
- Publication number
- DK0922102T3 DK0922102T3 DK97931275.8T DK97931275T DK0922102T3 DK 0922102 T3 DK0922102 T3 DK 0922102T3 DK 97931275 T DK97931275 T DK 97931275T DK 0922102 T3 DK0922102 T3 DK 0922102T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor agonists
- growth factor
- hepatocyte growth
- applications
- factor receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2121596P | 1996-07-03 | 1996-07-03 | |
PCT/US1997/010688 WO1998000543A1 (en) | 1996-07-03 | 1997-06-20 | Hepatocyte growth factor receptor agonists and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0922102T3 true DK0922102T3 (da) | 2010-08-16 |
Family
ID=21803007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97931275.8T DK0922102T3 (da) | 1996-07-03 | 1997-06-20 | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf |
Country Status (11)
Country | Link |
---|---|
US (1) | US6099841A (da) |
EP (1) | EP0922102B1 (da) |
JP (1) | JP2000515735A (da) |
AT (1) | ATE465257T1 (da) |
AU (1) | AU729029B2 (da) |
CA (1) | CA2258153C (da) |
DE (1) | DE69739856D1 (da) |
DK (1) | DK0922102T3 (da) |
IL (1) | IL127558A0 (da) |
WO (1) | WO1998000543A1 (da) |
ZA (1) | ZA975851B (da) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
ES2368823T3 (es) * | 1998-01-26 | 2011-11-22 | Genentech, Inc. | Anticuerpos del receptor 4 de muerte (dr4) y usos de los mismos. |
WO2001005955A2 (en) * | 1999-07-14 | 2001-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Animals comprising human hepatocellular tissue |
EP1142590B8 (en) * | 1999-10-29 | 2008-11-26 | AnGes MG, Inc. | Gene therapy for diabetic ischemic disease |
US20080241835A1 (en) * | 1999-11-01 | 2008-10-02 | Genentech, Inc. | Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
CA2452445C (en) * | 2000-06-29 | 2011-02-15 | North Shore-Long Island Jewish Health System | Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
EP1516185A4 (en) * | 2001-12-27 | 2007-06-20 | Van Andel Res Inst | PRESENTATION OF MONOCLONAL ANTIBODIES AND TREATMENT OF TUMORS EXPRESSING MET AND BINDING THE HEPATOCYTIC GROWTH FACTOR |
EP2075256A2 (en) | 2002-01-14 | 2009-07-01 | William Herman | Multispecific binding molecules |
US9701754B1 (en) | 2002-10-23 | 2017-07-11 | City Of Hope | Covalent disulfide-linked diabodies and uses thereof |
WO2004072117A2 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
WO2004093892A2 (en) * | 2003-04-16 | 2004-11-04 | Genentech, Inc. | Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization |
US20040208876A1 (en) * | 2003-04-18 | 2004-10-21 | Kim Kyung Jin | Monoclonal antibodies to hepatocyte growth factor |
TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
ITMI20031127A1 (it) | 2003-06-05 | 2004-12-06 | Uni Degli Studi Del Piemont E Orientale Am | Anticorpi anti-hgf-r e loro uso |
HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
EP2385069A3 (en) | 2003-11-12 | 2012-05-30 | Biogen Idec MA Inc. | Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
WO2005108424A1 (en) * | 2004-05-06 | 2005-11-17 | Genentech, Inc. | Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use |
US20060003931A1 (en) * | 2004-05-06 | 2006-01-05 | Genentech, Inc. | Crystal structure of the hepatocyte growth factor and methods of use |
DE602005022474D1 (de) * | 2004-10-20 | 2010-09-02 | Peas Inst Ab | Beurteilung der biologischen aktivität von hgf (hepatocyte growth factor) |
NZ556788A (en) | 2005-01-05 | 2011-03-31 | Biogen Idec Inc | Humanized CRIPTO binding molecules with CDRs from murine B3F6 |
CN101102788A (zh) * | 2005-01-24 | 2008-01-09 | 克霖固鲁制药股份有限公司 | 移植器官纤维化抑制剂 |
WO2006093211A1 (ja) * | 2005-03-02 | 2006-09-08 | Mitsubishi Pharma Corporation | 抗ウイルス剤 |
RU2404193C2 (ru) * | 2005-03-25 | 2010-11-20 | Дженентек, Инк. | Способ лечения опухоли у субъекта |
JP2008533991A (ja) * | 2005-03-25 | 2008-08-28 | ジェネンテック・インコーポレーテッド | 肺癌におけるc−met突然変異 |
EP1863519B1 (en) | 2005-03-31 | 2013-09-25 | The General Hospital Corporation | Modulating hgf/hgfr activity for treating lymphodema |
JP2008545753A (ja) * | 2005-06-02 | 2008-12-18 | ギャラクシー バイオテック, エルエルシー | 抗体で脳腫瘍を処置する方法 |
JP5137818B2 (ja) | 2006-03-20 | 2013-02-06 | 生化学工業株式会社 | 関節リウマチの処置剤 |
EP1996716B1 (en) | 2006-03-20 | 2011-05-11 | The Regents of the University of California | Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
JP2010514692A (ja) | 2006-12-20 | 2010-05-06 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物 |
CA2698343C (en) | 2007-09-04 | 2018-06-12 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection |
WO2009111644A2 (en) * | 2008-03-05 | 2009-09-11 | The Regents Of The University Of Michigan | Compositions and methods for diagnosing and treating pancreatic cancer |
ES2712732T3 (es) | 2009-02-17 | 2019-05-14 | Cornell Res Foundation Inc | Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico |
EP2504424A1 (en) | 2009-11-25 | 2012-10-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for hepatic differentiation of definitive endoderm cells |
RU2673908C2 (ru) | 2009-12-02 | 2018-12-03 | Имэджинэб, Инк. | Мини-антитела j591 и цис-диатела для направленной доставки простата-специфичного мембранного антигена (psma) человека и способы их применения |
JP2013532627A (ja) | 2010-07-01 | 2013-08-19 | 武田薬品工業株式会社 | cMET阻害剤とHGFおよび/またはcMETに対する抗体との組み合わせ |
DK2591099T3 (da) | 2010-07-09 | 2021-02-15 | Bioverativ Therapeutics Inc | Kimære koagulationsfaktorer |
WO2012059562A1 (en) | 2010-11-03 | 2012-05-10 | Argen-X-Bv | C-met antibody combinations |
US9738707B2 (en) | 2011-07-15 | 2017-08-22 | Biogen Ma Inc. | Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto |
EP2773660A2 (en) | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
CA2860579A1 (en) | 2012-01-10 | 2013-07-18 | Biogen Idec Ma Inc. | Enhancement of transport of therapeutic molecules across the blood brain barrier |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
EP2968498A4 (en) | 2013-03-15 | 2016-09-07 | Biogen Ma Inc | PREPARATIONS CONTAINING FACTOR IX POLYPEPTIDE |
WO2015056713A1 (ja) * | 2013-10-15 | 2015-04-23 | 国立大学法人東京大学 | c-Metタンパク質アゴニスト |
BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
IL250902B (en) | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and preparations |
EP3954993A1 (en) | 2015-02-04 | 2022-02-16 | Bristol-Myers Squibb Company | Methods of selecting therapeutic molecules |
EP3253875B1 (en) | 2015-02-04 | 2020-01-08 | H. Hoffnabb-La Roche Ag | Tau antisense oligomers and uses thereof |
CA2994951A1 (en) | 2015-08-07 | 2017-02-16 | Imaginab, Inc. | Antigen binding constructs to target molecules |
GB201611123D0 (en) * | 2016-06-27 | 2016-08-10 | Euremab Srl | Anti met antibodiesand uses thereof |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
WO2018147960A1 (en) | 2017-02-08 | 2018-08-16 | Imaginab, Inc. | Extension sequences for diabodies |
IT201800000535A1 (it) | 2018-01-03 | 2019-07-03 | Procedimenti per la cura del cancro. | |
AU2020224136A1 (en) | 2019-02-21 | 2021-09-02 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-MET antibodies and bispecific antigen binding molecules that bind MET |
JP2022541850A (ja) * | 2019-07-26 | 2022-09-27 | アンビス メディスンズ,インク. | 肝細胞を産生するための方法および組成物 |
CA3146933A1 (en) | 2019-09-16 | 2021-03-25 | Marcus KELLY | Radiolabeled met binding proteins for immuno-pet imaging |
WO2024050466A1 (en) | 2022-09-01 | 2024-03-07 | Regeneron Pharmaceuticals, Inc. | Methods of treating non-small cell lung cancer using mesenchymal epithelial transition factor (met)-targeted agents |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5362716A (en) * | 1989-12-27 | 1994-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines |
US5648273A (en) * | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
JP2750372B2 (ja) * | 1990-06-19 | 1998-05-13 | 敏一 中村 | 賢疾患治療剤 |
US6566098B1 (en) * | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
EP0584125B1 (en) * | 1991-05-10 | 1997-07-16 | PHARMACIA & UPJOHN S.p.A. | Truncated forms of the hepatocyte growth factor (hgf) receptor |
US5227158A (en) * | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
WO1994004679A1 (en) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DE69333807T2 (de) * | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5316921A (en) * | 1992-05-18 | 1994-05-31 | Genentech, Inc. | Single-chain hepatocyte growth factor variants |
US5328837A (en) * | 1992-05-18 | 1994-07-12 | Genentech, Inc. | Hepatocyte growth factor protease domain variants |
AU4528493A (en) * | 1992-06-04 | 1994-01-04 | Regents Of The University Of California, The | In vivo gene therapy with intron-free sequence of interest |
DE69310525T2 (de) * | 1992-09-16 | 1997-10-02 | Genentech Inc | Schutz gegen leberschäden mit hgf |
WO1994009969A1 (de) | 1992-10-28 | 1994-05-11 | Max Born Inst Fuer Nichtlinear | Metall/kunststoff-verbundkörper, verfahren zu dessen herstellung und vorrichtung zur ausführung des verfahrens |
RU2139092C1 (ru) | 1993-06-03 | 1999-10-10 | Терапьютик Антибодиз Инк. | Фрагменты антител в терапии |
US5464815A (en) * | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US8200624B2 (en) | 2010-07-20 | 2012-06-12 | Sybase, Inc. | Membership tracking and data eviction in mobile middleware scenarios |
-
1997
- 1997-06-20 IL IL12755897A patent/IL127558A0/xx unknown
- 1997-06-20 JP JP10504193A patent/JP2000515735A/ja not_active Ceased
- 1997-06-20 CA CA002258153A patent/CA2258153C/en not_active Expired - Lifetime
- 1997-06-20 WO PCT/US1997/010688 patent/WO1998000543A1/en active Application Filing
- 1997-06-20 DE DE69739856T patent/DE69739856D1/de not_active Expired - Lifetime
- 1997-06-20 AU AU34949/97A patent/AU729029B2/en not_active Expired
- 1997-06-20 AT AT97931275T patent/ATE465257T1/de not_active IP Right Cessation
- 1997-06-20 DK DK97931275.8T patent/DK0922102T3/da active
- 1997-06-20 EP EP97931275A patent/EP0922102B1/en not_active Expired - Lifetime
- 1997-06-27 US US08/884,669 patent/US6099841A/en not_active Expired - Lifetime
- 1997-07-01 ZA ZA975851A patent/ZA975851B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CA2258153C (en) | 2004-08-17 |
ATE465257T1 (de) | 2010-05-15 |
IL127558A0 (en) | 1999-10-28 |
AU729029B2 (en) | 2001-01-25 |
CA2258153A1 (en) | 1998-01-08 |
EP0922102B1 (en) | 2010-04-21 |
AU3494997A (en) | 1998-01-21 |
WO1998000543A1 (en) | 1998-01-08 |
DE69739856D1 (de) | 2010-06-02 |
JP2000515735A (ja) | 2000-11-28 |
ZA975851B (en) | 1999-01-04 |
US6099841A (en) | 2000-08-08 |
EP0922102A1 (en) | 1999-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0922102T3 (da) | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf | |
DK1053256T3 (da) | Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf | |
EP1746160A3 (en) | Hepatocyte growth factor receptor antagonists and uses thereof | |
DK1181319T3 (da) | Kimære DR4-antistoffer og anvendelser deraf | |
DE69838147D1 (de) | Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität | |
IL159527A0 (en) | Human dr4 antibodies and uses thereof | |
TR199902818T2 (xx) | Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler. | |
PT1526172E (pt) | Processo para a replicação de vírus influenza em cultura celular e os vírus influenza que podem ser obtidos pelo processo | |
BR0206985A (pt) | Anticorpos modificados e métodos de uso | |
TR200000927T2 (tr) | Prostaglandin agonistleri ve kemik bozukluklarının tedavisi | |
ATE405650T1 (de) | Produktion von ganzen antikörpern in prokaryontischen zellen | |
WO1999045098A3 (en) | Delivery or proteins into eukaryotic cells with recombinant yersinia | |
ES2177316T3 (es) | Anticuerpos humanos antifacotores ix/ixa. | |
NO971341D0 (no) | Promoter for reseptor tyrosinkinase TIE | |
DE69120287T2 (de) | Aminosulfonylharnstoff-acat-inhibitoren | |
DK1196442T3 (da) | VGF-polypeptider og fremgangsmåder til behandling af VGF-relaterede lidelser | |
EA200000875A1 (ru) | Белки, взаимодействующие с каспазой-8 | |
DK1196188T3 (da) | VGF-selektive monoklonale antistoffer og deres anvendelse til behandling af VGF-relaterede lidelser | |
DK1159426T3 (da) | Kloning og udtryk af Haemophilus somnus transferrin-bindende proteiner | |
UA30435A (uk) | Спосіб визначення онкологічного маркеру в сироватці крові | |
DK293790D0 (da) | Fremgangsmaade og sammensaetninger til behandling af pattedyrsinfektioner under anvendelse af praeparater omfattende gift fra hymenoptera, proteinagtige komponenter eller polypeptidkomponenter heraf eller analoger til disse proteinagtige komponenter eller polypeptidkomponenter |